Gossamer Bio Stock Performance
| GOSS Stock | USD 0.83 0.05 6.41% |
The company retains a Market Volatility (i.e., Beta) of 1.67, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gossamer Bio will likely underperform. Gossamer Bio right now retains a risk of 5.95%. Please check out Gossamer Bio treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Gossamer Bio will be following its current trending patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Gossamer Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Gossamer Bio is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1 | Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD - Seeking Alpha | 02/13/2025 |
2 | Disposition of 6430 shares by Christian Waage of Gossamer Bio at 1.1555 subject to Rule 16b-3 | 02/27/2025 |
3 | Acquisition by Faheem Hasnain of 1540000 shares of Gossamer Bio at 1.13 subject to Rule 16b-3 | 03/04/2025 |
4 | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 03/07/2025 |
5 | 3 Promising Penny Stocks With Over 100M Market Cap | 03/12/2025 |
6 | Gossamer Bio Q4 Earnings Snapshot | 03/13/2025 |
7 | Disposition of 13750 shares by Aranda Richard of Gossamer Bio at 16.4 subject to Rule 16b-3 | 03/14/2025 |
8 | H.C. Wainwright maintains Buy on Gossamer Bio, 10 target - Investing.com | 03/18/2025 |
9 | Is Gossamer Bio, Inc. The Hot Biotech Stock Under 5 | 03/26/2025 |
10 | Acquisition by Bryan Giraudo of 96667 shares of Gossamer Bio at 1.36 subject to Rule 16b-3 | 04/13/2025 |
| Begin Period Cash Flow | 32.1 M |
Gossamer |
Gossamer Bio Relative Risk vs. Return Landscape
If you would invest 92.00 in Gossamer Bio on January 13, 2025 and sell it today you would lose (9.00) from holding Gossamer Bio or give up 9.78% of portfolio value over 90 days. Gossamer Bio is currently generating 0.0138% in daily expected returns and assumes 5.9457% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than Gossamer, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gossamer Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gossamer Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gossamer Bio, and traders can use it to determine the average amount a Gossamer Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GOSS |
Estimated Market Risk
| 5.95 actual daily | 53 53% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Gossamer Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gossamer Bio by adding Gossamer Bio to a well-diversified portfolio.
Gossamer Bio Fundamentals Growth
Gossamer Stock prices reflect investors' perceptions of the future prospects and financial health of Gossamer Bio, and Gossamer Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gossamer Stock performance.
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (3.85) % | ||||
| Current Valuation | 95.82 M | ||||
| Shares Outstanding | 227.22 M | ||||
| Price To Earning | (4.61) X | ||||
| Price To Book | 6.36 X | ||||
| Price To Sales | 1.63 X | ||||
| Revenue | 114.7 M | ||||
| Gross Profit | 114.7 M | ||||
| EBITDA | (39.97 M) | ||||
| Net Income | (56.53 M) | ||||
| Cash And Equivalents | 304.38 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 202.88 M | ||||
| Debt To Equity | 3.86 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.13 X | ||||
| Cash Flow From Operations | (3.47 M) | ||||
| Earnings Per Share | (0.25) X | ||||
| Market Capitalization | 187.46 M | ||||
| Total Asset | 315.29 M | ||||
| Retained Earnings | (1.27 B) | ||||
| Working Capital | 264.88 M | ||||
| Current Asset | 441.63 M | ||||
| Current Liabilities | 39.84 M | ||||
About Gossamer Bio Performance
Assessing Gossamer Bio's fundamental ratios provides investors with valuable insights into Gossamer Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Gossamer Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (8.65) | (9.08) | |
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.22) | (0.21) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (1.92) | (1.82) |
Things to note about Gossamer Bio performance evaluation
Checking the ongoing alerts about Gossamer Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gossamer Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gossamer Bio had very high historical volatility over the last 90 days | |
| Gossamer Bio has some characteristics of a very speculative penny stock | |
| Gossamer Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 114.7 M. Net Loss for the year was (56.53 M) with profit before overhead, payroll, taxes, and interest of 114.7 M. | |
| Gossamer Bio currently holds about 304.38 M in cash with (3.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gossamer Bio has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
- Analyzing Gossamer Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gossamer Bio's stock is overvalued or undervalued compared to its peers.
- Examining Gossamer Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gossamer Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gossamer Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gossamer Bio's stock. These opinions can provide insight into Gossamer Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.